Magellan Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-1,678,195
Closed -$116M 85
2025
Q2
$116M Sell
1,678,195
-928,021
-36% -$63.1M 1.32% 28
2025
Q1
$181M Sell
2,606,216
-206,565
-7% -$17.1M 2.2% 21
2024
Q4
$242M Buy
2,812,781
+400,953
+17% +$43.4M 2.66% 17
2024
Q3
$287M Buy
2,411,828
+508,548
+27% +$67.8M 2.86% 15
2024
Q2
$272M Buy
+1,903,280
New +$252M 2.59% 15

Other funds holding NVO

Magellan Asset Management's NVO Position: Q3 2025 in Review

Magellan Asset Management sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 1,678,195 shares — an estimated $116M sold.

Magellan Asset Management first reported a position in NVO in Q2 2024 and held it in 5 quarters. The position peaked at $287M in Q3 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Magellan Asset Management reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Magellan Asset Management sold 1,678,195 Novo Nordisk shares in Q3 2025, an estimated $116M.
  • Magellan Asset Management first reported a position in Novo Nordisk in Q2 2024 and held it in 5 quarters.
  • Magellan Asset Management's Novo Nordisk position peaked at $287M in Q3 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Magellan Asset Management's 13F filing for Q3 2025, filed 10 Nov 2025.